Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Tu Dan Nguyen

Sports Medicine Sugar Land, TX Medical Doctor

NPI 1356753057 CMS profile 2790144

14023 Southwest Fwy, Sugar Land, TX 77478

Open in the dashboard

General payments

$2,548

121 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Tu Dan Nguyen of Sugar Land, TX is reported in the CMS Open Payments database as having received $2,548 across 121 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $101 1
2023 General $37 2
2022 General $48 2
2021 General $82 5
2020 General $1,379 69
2019 General $901 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tu Dan Nguyen
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Tu Dan Nguyen were reported at $0. Among 1,257 Sports Medicine profiles paid that year, the median was $114 and the middle half received between $39 and $293.

Show as a table
Year Tu Dan Nguyen Sports Medicine median Middle half National median
2019 $901 $119 $35–$362 $163
2020 $1,379 $77 $24–$275 $114
2021 $82 $104 $28–$340 $132
2022 $48 $94 $31–$272 $149
2023 $37 $91 $34–$271 $160
2024 $101 $126 $38–$294 $164
2025 $0 $114 $39–$293 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Amarin Pharma Inc. $477 27 payments
  2. Novo Nordisk Inc $414 25 payments
  3. AstraZeneca Pharmaceuticals LP $264 17 payments
  4. Flexion Therapeutics, Inc. $249 3 payments
  5. Galderma Laboratories, L.P. $175 2 payments
  6. Horizon Therapeutics plc $120 1 payment
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $106 6 payments
  8. Medtronic, Inc. $101 1 payment
  9. Teva Pharmaceuticals USA, Inc. $94 6 payments
  10. Lilly USA, LLC $74 6 payments
  11. Other $475 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,548 121 payments
Products named General payments · program years 2019–2024
  1. Vascepa $436 25 payments
  2. Zilretta $249 3 payments
  3. FARXIGA $236 15 payments
  4. Ozempic $164 12 payments
  5. Saxenda $161 5 payments
  6. RYBELSUS $131 9 payments
  7. INTELLIS ADAPTIVESTIM $101 1 payment
  8. MYRBETRIQ $71 4 payments
  9. SYMBICORT $70 3 payments
  10. VAC VERAFLO $64 1 payment
  11. Other $827 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

733

Median for Family Practice: 1,826

Drug cost

$40,192

Median for Family Practice: $120,094

Branded share of claims

7%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 12 $16,383
Mounjaro Tirzepatide Brand 13 $15,870
Atorvastatin Calcium Generic 76 $741
Rosuvastatin Calcium Generic 25 $623
Pravastatin Sodium Generic 40 $549
Gabapentin Generic 55 $527
Losartan Potassium Generic 45 $472
Valsartan Generic 23 $441
Amlodipine Besylate Generic 59 $418
Omeprazole Generic 27 $416

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$23,094

Of which drugs: $3,214

Medicare patients

137

Average age 72

Services billed

363

83 women, 54 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 42%
Arthritis 40%
Chronic kidney disease 33%
Ischemic heart disease 24%
Depression 20%
Osteoporosis 19%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 13 13 $1,064

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

121 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record